Eyepoint Pharmaceuticals to Reveal Q3 Earnings on November 6

Eyepoint Pharmaceuticals (NASDAQ:EYPT) is set to announce its third quarter earnings for the fiscal year 2025 on Thursday, November 6, 2025, prior to the market opening. Analysts project that the company will report a loss of $0.77 per share, with expected revenue reaching $3.329 million for the quarter. Interested parties can access details on the earnings call scheduled for Wednesday, November 5, 2025, at 08:30 AM ET.

In its previous earnings report on August 6, 2025, Eyepoint Pharmaceuticals posted a loss of $0.85 per share, falling short of the consensus estimate of $0.67 by $0.18. The company’s revenue for that quarter amounted to $5.33 million, which was below analysts’ expectations of $6.82 million. Additionally, Eyepoint reported a negative return on equity of 63.80% and a net margin of 337.93%.

Analysts currently anticipate that Eyepoint will register an average loss of $2 per share for the current fiscal year, with expectations of a $3 loss per share for the following fiscal year.

Stock Performance and Market Position

On the stock market, Eyepoint Pharmaceuticals opened at $11.73 on Thursday. The company has a 50-day moving average of $12.80 and a 200-day moving average of $9.99. Eyepoint holds a market capitalization of $808.55 million, with a price-to-earnings ratio of -4.38 and a beta of 1.95. Over the past year, the stock has fluctuated between a low of $3.91 and a high of $14.91.

Changes in Institutional Holdings

Recent trading activity indicates notable changes among institutional investors in Eyepoint Pharmaceuticals. Rhumbline Advisers increased its holdings by 11.0% in the second quarter, now owning 96,280 shares valued at approximately $906,000 after acquiring an additional 9,548 shares. Similarly, American Century Companies Inc. raised its stake by 57.8%, bringing its total to 67,612 shares, valued at $636,000.

Invesco Ltd. significantly expanded its holdings, increasing by 199.8%, now owning 128,772 shares worth $1.212 million. Raymond James Financial Inc. and Adage Capital Partners GP L.L.C. also boosted their positions, with the latter owning 6,800,000 shares valued at approximately $63.988 million.

Overall, institutional investors control 99.41% of Eyepoint Pharmaceuticals’ stock, reflecting strong interest in the company’s potential.

Eyepoint Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics aimed at improving the lives of patients suffering from serious retinal diseases. The company utilizes its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery, positioning itself as a key player in the biopharmaceutical field.

As the earnings announcement approaches, stakeholders will be keen to see if Eyepoint can meet or exceed the expectations set by analysts in what is becoming a closely watched financial report.